|
Current Clinical Trials (active):
Regeneron Pharmaceuticals, Inc
VIEW 1, Protocol # VGFT OD 0605
A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration
Genentech, Inc
RIDE, Protocol # FVF4168g
A Phase III, Double-Masked, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus
Regeneron Pharmaceuticals, Inc
Protocol # VGFT-OD-0702
An Open-Label, Long-Term, Safety, and Tolerability Study of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration
Regeneron Pharmaceuticals, Inc
Copernicus, Protocol # VGFT-OD-0819
A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
Genentech, Inc
Horizon, FVF3426g
An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Choroidal Neovascularization (CNV) Secondary to Age Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) Who Have Completed a Genentech Sponsored Ranibizumab Study
|
